share_log

Clearmind Medicine | EFFECT: Others

Clearmind Medicine | EFFECT:其他

美股sec公告 ·  01/22 00:00
Moomoo AI 已提取核心信息
Clearmind Medicine Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring the company's submission effective as of January 19, 2024. The submission, identified by Accession Number 0001213900-24-004506 and Submission Type POS AM, pertains to File Number 333-270859. This notice of effectiveness from the SEC is a crucial step for Clearmind Medicine, indicating that the regulatory body has reviewed and accepted the company's filing.
Clearmind Medicine Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring the company's submission effective as of January 19, 2024. The submission, identified by Accession Number 0001213900-24-004506 and Submission Type POS AM, pertains to File Number 333-270859. This notice of effectiveness from the SEC is a crucial step for Clearmind Medicine, indicating that the regulatory body has reviewed and accepted the company's filing.
Clearmind Medicine Inc.取得了重要的里程碑,美国证券交易委员会(SEC)宣布该公司的申请自2024年1月19日起生效。该提交的文件由注册号 0001213900-24-004506 和提交类型 POS AM 确定,与文件编号为 333-270859 有关。美国证券交易委员会的这份生效通知对Clearmind Medicine来说是至关重要的一步,这表明监管机构已经审查并接受了该公司的申请。
Clearmind Medicine Inc.取得了重要的里程碑,美国证券交易委员会(SEC)宣布该公司的申请自2024年1月19日起生效。该提交的文件由注册号 0001213900-24-004506 和提交类型 POS AM 确定,与文件编号为 333-270859 有关。美国证券交易委员会的这份生效通知对Clearmind Medicine来说是至关重要的一步,这表明监管机构已经审查并接受了该公司的申请。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息